Medical-device maker SMT seeks ‘optimum’ pricing to balance access and quality
Company IPO to open this week, price band between ₹327 to ₹ 344 per equity share
Sahajanand Medical Technologies Limited (SMT), a domestic medical device manufacturer, is targeting "optimum" pricing for its products to balance accessibility and quality in both developed and domestic markets, says Managing Director and CEO Bhargav Kotadia. SMT has expanded its cardio-vascular product offerings into markets dominated by multinational corporations, leveraging its clinical efficacy, manufacturing scale, and clinical trial evidence.
In India, the company aims to strike a balance between affordability and product quality, avoiding excessive pricing that could compromise performance. SMT's IPO, scheduled for October 19, 2026, seeks to raise ₹475 crore by offering up to 13.8 million equity shares at a price band of ₹327 to ₹344 per share. The company, which derives 70% of its ₹1.21 billion revenue from developed markets, emphasizes clinical evidence and user experience to compete with multinational brands in markets like Germany.
The IPO includes an offer for sale by the promoter family, employee stock options, and participation from investment firms such as Samara Capital Markets Holding Limited and Kotak Pre-IPO Opportunities Fund.
Written by urgent.news from Hindu BusinessLine's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
